Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01548287 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
NCT01548287 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 164 participants.
The verdict
NCT01548287, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
Study Summary
This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.
Interventions
- OTHER Placebo
- DRUG AZD5213
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01548287
The ClinicalTrials.gov registry entry for NCT01548287 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01548287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01548287 about?
NCT01548287 is a clinical study titled "A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment". This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.
What is the current status of trial NCT01548287?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2012-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01548287?
The interventions under investigation include: Placebo (OTHER), AZD5213 (DRUG).
Who is sponsoring clinical trial NCT01548287?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.